Discover why Crispr Therapeutics AG is a strong buy with FDA-approved Casgevy, a promising pipeline, and major growth ...
Zacks Investment Research on MSN
CRISPR Therapeutics AG (CRSP) is attracting investor attention: Here is what you should know
CRISPR Therapeutics AG (CRSP) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to ...
Sofi-cel is an investigational, potential first-in-class, allogeneic, anti-CD7 CAR-T cell therapy currently under evaluation in a pivotal trial (T-RRex) for patients with relapsed or refractory (R/R) ...
Parse Biosciences, a leading provider of accessible and scalable single cell sequencing solutions, today announced the launch of Evercodetm Whole Blood Fixation, a new kit that enables immediate ...
Key opportunities in the market include leveraging CRISPR's precision for improved crop traits, meeting food security demands amid climate change, and sustainable agriculture trendsDublin, Dec. 09, ...
Now, it’s worth noting Stock Advisor's total average return is 991% — a market-crushing outperformance compared to 195% for ...
High-flying, unprofitable pure-play quantum computing stocks will likely plunge if the bubble bursts. Tech giants that are ...
Dyadic International, Inc. ( DYAI) IAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 December 9, 2025 9:30 AM EST Good day, and welcome to the iAcessAlpha Virtual Best Ideas winter ...
Credo stock is now up more than 180% so far this year, demonstrating that there are outstanding opportunities for investors ...
Equity Insider News Commentary ? Traditional pharmaceutical strategies are giving ground as breakthrough approvals for gene therapies and mRNA platforms target previously untreatable rare diseases ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback